New FDA Rule Improves Labeling of Medications Used During Pregnancy and Lactation

The U.S. Food and Drug Administration's (FDA's) Pregnancy and Lactation Labeling Rule must help the healthcare providers to explain the pregnant and breastfeeding patients on the benefits and risks of taking a specific medication.

The labeling rule must provide a summary of the evidence-based risks, and replacing the previous that were too often misinterpreted, finds a new article published in Pediatric Allergy, Immunology and Pulmonology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

‘FDA rule improves labeling of medications that are used during pregnancy and lactation.’

Miriam Dinatale, DO, Leyla Sahin, MD, Tamara Johnson, MD, Tammie Brent Howard, RN, and Lynne Yao, MD, Food and Drug Administration, Silver Spring, MD, present a clear description of the new FDA labeling rule, how it is being implemented, and how it improves on the existing labeling system in the article entitled "Medication Use During Pregnancy and Lactation: Introducing the Pregnancy and Lactation Labeling Rule."

More than half of pregnant women report taking at least one medication. These new labeling requirements detail the risks of a prescription drug or biological product for the mother, fetus, breastfeeding infant, and women and men of reproductive potential.

"According to a recent study by the Centers for Disease Control and Prevention (CDC) on Family Growth in the U.S., approximately 50% of women between ages 15 and 44 responded that they intend to have a child in the future. Healthcare providers responsible for counseling patients who are pregnant, planning to become pregnant, and those who are breastfeeding need a reliable source of information about prescription medications," says Pediatric Allergy, Immunology, and Pulmonology Editor-in-Chief Mary Cataletto, MD, Professor of Clinical Pediatrics, Stony Brook University School of Medicine.

"The new labeling requirement provides a more user-friendly presentation of studies, registries, and available information that can be used to assist providers in discussing medication risks and benefits with their patients."



Source: Eurekalert